This risk for ketoacidosis can be simply mitigated by not using SGLT2 inhibitors in individuals with type 1 diabetes and ensuring that insulin doses are not omitted in insulin-treated patients with T2D. The gene discussed is SLC5A2; the disease is type 1 diabetes mellitus.